ripasudil | 217971-63-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: ripasudil
• 英文别名: 1-(4-Fluoro-5-isoquinolinesulfonyl)-2-methylhexahydro-1H-1,4-diazepine；4-Fluoro-5-((2-methyl-1,4-diazepan-1-yl)sulfonyl)isoquinoline；4-fluoro-5-[(2-methyl-1,4-diazepan-1-yl)sulfonyl]isoquinoline
• CAS: 217971-63-6
• 化学式: C₁₅H₁₈FN₃O₂S
• 分子量: 323.391
• InChiKey: QSKQVZWVLOIIEV-UHFFFAOYSA-N

物化性质

• 沸点：
  497.2±55.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  二氯乙酸 、 ripasudil 以 水 为溶剂， 反应 0.17h， 以81%的产率得到ripasudil dichloroacetic acid salt
  参考文献：
  名称：

  ROCK抑制剂-二氯乙酸复盐及其制备方法和 用途

  摘要：

  本发明涉及药物化学和药物治疗学领域，具体涉及一种ROCK抑制剂‑二氯乙酸复盐或其药学上可接受的盐，它们的制备方法、含有这些化合物的药用组合物以及它们的医药用途，特别是在制备预防和/或治疗肺动脉高压、缺血性脑卒中、蛛网膜下腔出血等心脑血管疾病的药物中的应用。

  公开号：

  CN109734701B

文献信息

• NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF
  申请人：Gomi Noriaki

  公开号：US20130144054A1

  公开（公告）日：2013-06-06

  The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.

  本发明提供了一种能够在工业上生产目标产品的方法，即一种由上述公式（I）表示的化合物或其盐，该化合物对预防和治疗脑血管疾病（如脑梗死、脑出血、蛛网膜下腔出血和脑水肿）特别是对预防和治疗青光眼具有用处，即使在大规模生产时也能高产率地生产，而且不对环境造成负面影响。本发明提供了一种生产由公式（I）表示的化合物或其盐的方法，其中该方法包括以下步骤：在至少选择自腈溶剂、酰胺溶剂、亚砜溶剂和脲溶剂组成的群中选择至少一种溶剂和一种碱的条件下，将由公式（III）表示的化合物或其盐与由公式（II）表示的化合物反应。
• [EN] POLYMERIC CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS POLYMÈRES ET LEURS UTILISATIONS
  申请人：FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIG PRINCIPE FELIPE

  公开号：WO2020193802A1

  公开（公告）日：2020-10-01

  The present invention relates to novel chemical entities comprising a polymeric carrier incorporating covalently linked drug(s) as well as their pharmaceutical compositions containing the said polymer-drug conjugates as pharmaceutical agents and their uses thereof in therapy and, more particularly, but not exclusively, to novel conjugates having attached thereto a targeting moiety, an imaging agent and one or more therapeutic agents to promote axonal growth and for the treatment of neurodegenerative and inflammatory diseases, central nervous system traumatic injuries and cancer.

  本发明涉及一种新型化学实体，包括将药物共价连接到聚合载体中的药物，以及包含所述聚合物-药物共轭物作为药物代理的药物组合物，以及它们在治疗中的用途，更具体地说，但不限于，涉及附有靶向基团、成像剂和一个或多个治疗剂的新型共轭物，用于促进轴突生长和治疗神经退行性和炎症性疾病、中枢神经系统创伤性损伤和癌症。
• ISOQUINOLINESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：Hidaka, Hiroyoshi

  公开号：EP1074545A1

  公开（公告）日：2001-02-07

  This invention relates to isoquinolinesulfonamide derivatives represented by the following formula (1): wherein A represents a linear or branched alkylene group, R1 represents a hydrogen atom, an hydroxyl, alkoxy or alkyl group or the like, R2 represents a hydrogen atom, an alkyl group or the like, R3 represents a hydrogen atom, an alkyl group or the like, and R4 and R5 may be the same or different and individually represent hydrogen atoms or lower alkyl groups; N-oxides and salts thereof; and solvates thereof. This invention is also concerned with pharmaceutical compositions, which contain the derivatives, N-oxides, salts, or solvates. These derivatives, N-oxides, salts, and solvates have viral proliferation inhibiting activities and are useful as AIDS therapeutics.

  本发明涉及下式（1）所代表的异喹啉磺酰胺衍生物： 其中 A 代表直链或支链亚烷基，R1 代表氢原子、羟基、烷氧基或烷基或类似基团，R2 代表氢原子、烷基或类似基团，R3 代表氢原子、烷基或类似基团，R4 和 R5 可以相同或不同，且各自代表氢原子或低级烷基；其 N-氧化物和盐；以及其溶解物。本发明还涉及含有这些衍生物、N-氧化物、盐或溶液的药物组合物。这些衍生物、N-氧化物、盐和溶液具有抑制病毒增殖的活性，可用作艾滋病治疗药物。
• Production method of 1,4-diazepane derivatives
  申请人：Kowa Co., Ltd.

  公开号：EP2818463A1

  公开（公告）日：2014-12-31

  The present invention provides a method for producing a compound represented by the following formula (IV) or a salt thereof: wherein R3 represents a C1-4 alkyl group, Ns represents a nosyl group, and P1 represents a hydrogen atom, a C1-6 alkoxycarbonyl group, a C6-10 aryl C1-3 alkyl group, or a C6-10 aryl C1-3 alkoxycarbonyl group comprising reacting a compound represented by the following formula (V): wherein R3, P1 and Ns are the same as described above, in a solvent in a presence of triphenylphosphine and diisopropyl azodicarboxylate.

  本发明提供了一种生产下式（IV）代表的化合物或其盐的方法： 其中 R3 代表 C1-4 烷基，Ns 代表对甲苯磺酸基团，P1 代表氢原子、C1-6 烷氧基羰基、C6-10 芳基 C1-3 烷基或 C6-10 芳基 C1-3 烷氧基羰基 包括使下式（V）代表的化合物反应： 其中 R3、P1 和 Ns 与上述相同、 在三苯基膦和偶氮二甲酸二异丙酯存在下，在溶剂中进行反应。
• NOVEL AQUEOUS COMPOSITION
  申请人：Kowa Company, Ltd.

  公开号：EP3231429A1

  公开（公告）日：2017-10-18

  A technique is provided for suppressing the crystal precipitation of an aqueous composition containing a halogenated isoquinoline derivative during low-temperature preservation. An aqueous composition comprising a compound represented by Formula (1): wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and brimonidine or a salt thereof.

  提供了一种在低温保存过程中抑制含有卤代异喹啉衍生物的水性组合物晶体析出的技术。一种水性组合物包含由式（1）代表的化合物： 其中 X 代表卤原子 或其盐，或该化合物或其盐的溶液，以及溴莫尼定或其盐。